No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 32 of the 38 quarters in the window, leaving 6 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 39
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T15:07:07.259Z. Latest historical point 2026-08-06. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for InflaRx N.V. (IFRX) stock was $1.64 as of Oct 6, 2026, 11:04 AM EDT, down 2.38% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +6.3% · 3-year avg -13.3%/yr · 5-year avg -7.3%/yr
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States.
Biotechnology · Jena, TH
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2022-12-31 · EUR
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.07
Revenue Est.
$6063.00
Last Quarter Results
EPS
$-0.09
vs Estimate
$-0.06
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1IFRX | $241.56M | $1.64 | -2.38% | +6.30% | -7.34% | N/A | N/A |
| 2GALT | $241.69M | $3.67 | -1.61% | -13.80% | +0.60% | +13.41% | vs IFRX |
| 3AKBA | $240.60M | $0.90 | -1.49% | -67.65% | -20.07% | -20.53% | vs IFRX |
| 4CAMP | $243.71M | $3.88 | -3.15% | +32.17% | N/A | N/A | vs IFRX |
| 5LFCR | $243.82M | $6.50 | -0.30% | -6.56% | -7.12% | -6.99% | vs IFRX |
| 6NAUT | $243.85M | $1.92 | +2.47% | +111.12% | -20.56% | N/A | vs IFRX |
N/A
$0.00
vs Estimate
$5996.00
Consensus Rating
Based on 9 analysts
Average Price Target
$7.70
+369.3% upside
Low
$2.93
Current
$1.64
High
$13.69
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | EUR -0.07 | EUR -0.06 | EUR -0.05 | 4 |
| Quarter ending Dec 2026 | EUR -0.07 | EUR -0.06 | EUR -0.05 | 4 |
| Quarter ending Mar 2027 | EUR -0.07 | EUR -0.07 | EUR -0.07 | 1 |
| Quarter ending Jun 2027 | EUR -0.08 | EUR -0.08 | EUR -0.08 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | EUR -0.31 | EUR -0.27 | EUR -0.21 | 4 |
| FY 2027 | EUR -0.50 | EUR -0.35 | EUR -0.24 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | EUR 5373.00 | EUR 5373.00 | EUR 5373.00 | 4 |
| Quarter ending Dec 2026 | EUR 5117.00 | EUR 5117.00 | EUR 5117.00 | 2 |
| Quarter ending Mar 2027 | EUR 0.00 | EUR 0.00 | EUR 0.00 | 0 |
| Quarter ending Jun 2027 | EUR 0.00 | EUR 0.00 | EUR 0.00 | 0 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | EUR 12691.00 | EUR 12691.00 | EUR 12691.00 | 3 |
| FY 2027 | EUR 16581.00 | EUR 16581.00 | EUR 16581.00 | 3 |
